Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cagrilintide/semaglutide - Novo Nordisk

Next Previous
Drug Profile

Cagrilintide/semaglutide - Novo Nordisk

Alternative Names: CagriSema; NN-9388; Semaglutide/Cagrilintide - Novo Nordisk

Latest Information Update: 21 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Class Antihyperglycaemics; Glucagon-like peptides; Hepatoprotectants; Obesity therapies; Urologics; Vascular disorder therapies
  • Mechanism of Action Amylin receptor agonists; Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Obesity
  • Phase III Type 2 diabetes mellitus
  • Phase II Alcoholic liver disorders; Diabetic neuropathies

Most Recent Events

  • 21 Jul 2026 Novo Nordisk withdraws prior to enrolment a phase II trial in Type 2 diabetes mellitus (Treatment-experienced)in the USA, Denmark, Greece, Malaysia, Serbia, Slovakia, Spain and Thailand (SC) (NCT07357740)
  • 09 Jul 2026 Novo Nordisk completes the phase III REIMAGINE 5 trial for Type 2 diabetes mellitus (Adjunctive treatment) in Argentina, USA, Australia, Brazil, Canada, Germany, Greece, Hungary, India, Israel, Poland, Romania, Spain and Taiwan (SC) (NCT06534411) (CTIS-2023-509600-15)
  • 09 Jul 2026 Novo Nordisk withdraws prior to enrolment a phase III trial in Obesity in the USA, Bulgaria, Denmark, Greece, Hungary, Malaysia, Poland, Portugal, Romania, Slovakia, South Africa, Switzerland, Taiwan and Thailand (SC) (NCT07357766)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top